Clinical trial
Treatment of Imminent Haematological Relapse in Patients With AML and MDS…
NCT00422890 · Technische Universität Dresden, Other · Completed
Key facts
| NCT number | NCT00422890 |
|---|---|
| Title | Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) |
| Lead sponsor | Technische Universität Dresden, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myeloid Leukemia, Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | 5-Azacytidin |
| Enrollment | 10 |
| Start date | Jan 1, 2007 |
| Primary completion | Dec 1, 2009 |
| First posted | Jan 17, 2007 |
| Last update posted | Jul 11, 2011 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: